Clinical Trials: Non-Hodgkin's Lymphoma

Alabama

Birmingham; Hematology and Oncology Associates of Alabama
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Huntsville; Oncology Specialities, P.C., Comprehensive Cancer Institute
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Arizona

Glendale; Palo Verde Hematology Oncology, Ltd.
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Tucson; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Tuscon, ; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Arkansas

Hot Springs ; Genesis Cancer Center
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Jonesboro; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

California

Bakersfield; Biogen Idec, Inc.
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R

Berkeley; Biogen Idec, Inc.
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R

Beverly Hills; Tower Cancer Research Foundation
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Beverly Hills; Biogen Idec, Inc.
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R

Beverly Hills, ; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Duarte; City of Hope
A Phase II Study of Yttrium-90-Labeled Anti-CD20 Monoclonal Antibody in Combination with High-Dose Beam (BCNU, Etoposide, Cytarabine and Melphalan) Followed by Autologous Stem Cell Transplantation for Patients with Poor Risk/Relapsed B-Cell Lymphoma

Duarte; City of Hope
A Phase 1B Study to Evaluate the Safety and Tolerability of AMG 655 in Combination with Bortezomib or Vorinostat in Subjects with Relapsed or Refractory Lymphoma

Duarte; City of Hope
A Phase II Study of Vorinstat (Suberoylanilide Hydroaxamic Acid)Plus Rituximab in Indolent Non-Hodgkin's Lymphoma

Duarte; City of Hope
An Open-Label , Single-Arm Phase II Study of RAD001 in Patients with Refractory Mantle Cell Lymphoma

Duarte; City of Hope
PHI-58 NCI# 7943:Phase I Study of GX15-070 (NSC #729280) and Bortezomib in Aggressive Relapsed/Recurrent Non-Hodgkin's Lymphoma

Duarte; City of Hope
A Pilot Study of Safety and Feasibility of Stem Cell Therapy for Aids Lymphoma Using Stem Cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs

Duarte; City of Hope
SWOG S0433: Iodine-131 Labeled Monoclonal Antibody (I-131 Tositumomab) in Combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab Therapy for Patients With Advanced Stage Diffuse Large B Cell NHL; A Phase II Study

Duarte; City of Hope
Long-Term Follow Up of Recipients of Gene Transfer Research at City of Hope

Duarte; City of Hope
PHII-059 NCI#1312: Phase II Trial of Depsipeptide in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma

Duarte; City of Hope
Obtaining Leukapheresed Peripheral Blood Mononuclear Cells from Mantle Cell Lymphoma Patients in Remission for Use in T Cell Program

Duarte; City of Hope
Genetic Epidemiology of Non-Hodgkin's Lymphoma (NHL)

Duarte; City of Hope
A Phase I Study of De-Immunized DI-Leu16-IL2 Immunocytokine in Patients with B-Cell Non-Hodgkin’s Lymphoma

Duarte; City of Hope
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for B–Cell Non–Hodgkin Lymphoma Using Zevalin®, Fludarabine and Melphalan

Duarte; City of Hope
SWOG S0350: Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol (Pegs) in Peripheral T-Cell Non-Hodgkin's Lymphoma

Duarte; City of Hope
High Dose Chemotherapy and Combination anti-HIV Therapy for HIV-Associated Hodgkin's and Non-Hodgkin's Lymphoma

Duarte; City of Hope
Multicenter Evaluation of Non-Hodgkins Lymphoma patterns and Outcomes of Care Within the National Comprehensive Cancer Network (NCCN)

Encinitas; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Fountain Valley; Compassionate Cancer Care Medical Group, Inc.
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

LaVerne; Wilshire Oncology Medical Group
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Los Angeles; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Montebello; Kenmar Research Institute
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Newport Beach; Research Site
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R

Vallejo; Research Site
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R

Colorado

Colorado Springs; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Denver; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Delaware

Newark; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Florida

Gainesville; University of Florida Shands Cancer Center, Solid Tumor Office, Clinical Trials
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Jacksonville; Baptist Cancer Institute
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Jacksonville; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

New Port Richey; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Ocala; Ocala Oncology Center
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Ocoee; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Orlando; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Pembroke Pines; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Pensacola; Hematology Oncology Associates
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

St. Petersburg; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

St. Petersburg; Research Site
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R

Winter park; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Georgia

Augusta; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Macon; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Idaho

Couer d'Alene; Research Site
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R

Illinois

Chicago; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Joilet; Biogen Idec, Inc.
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R

Maywood; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Springfield; Springfield Clinic, LLP
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Indiana

Beach Grove; St. Francis Cancer Research Foundation
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Indianapolis; Indiana University Cancer Center
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

New Albany; Cancer Care Center
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Iowa

Cedar Rapids; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Kansas

Kansas City; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Overland Park; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Overland Park; Research Site
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R

Kentucky

Lexington; Central Baptist Hospital Kentucky
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Louisiana

Anniston; Anniston Oncology
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Shreveport; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Maryland

Baltimore; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Massachusetts

Boston; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Michigan

Detroit; Research Site
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R

Detroit; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Grosse Pointe; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

St Joseph; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Minnesota

Maplewood; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Minneapolis; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

St. Louis Park; Biogen Idec, Inc.
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R

Mississippi

Tupelo; North Mississippi Hematology & Oncology Associates
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Missouri

Kansas City; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Lee's Summit; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

St. Louis; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Washington; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Montana

Billings; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Nebraska

Omaha; Hematology & Oncology Consultants, PC
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

New Jersey

Hackensack; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Morristown; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Neptune; Jersey Shore University Medical Center
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

New York

Albany; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Amsterdam; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Bronx; Fernanado J. Camacho M.D., & Mark A. Ramirez M.D., P.C.
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

East Setauket; Biogen Idec, Inc.
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R

Fresh Meadows; Queens Medical Associates
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Hudson; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Jamaica; Biomedical Research Alliance of New York
Use of Neulasta with chemotherapy in elderly patients with cancer

Latham; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

New Hyde Park; Biomedical Research Alliance of New York
Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia (CLL) Adults

New York; Mount Sinai Medical Center
An Open-label Phase II/III Study of Rituximab in Combination With Recombinant Human IL-2 for Relapsed Low-grade or Follicular Non-Hodgkin's Lymphoma in Patients Who Have Previously Failed Rituximab

New York; Mount Sinai Medical Center
An Open-labeled, Phase 2 Study of Rituximab in Combination With Recombinant Human IL-2 for Relapsed or Refractory Non-Hodgkin's Lymphoma of Intermediate or High-grade Histology

New York; Columbia University Medical Center
This is a phase II study in which patients will receive uniform doses of fludarabine and rituximab for low-grade lymphoma and chronic lymphocytic leukemia, and for responding patients who can tolerate it, CAMPATH will be given only during the final 2 months of treatment on this study.

New York; St Luke's Roosevelt Hospital
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

New York; Columbia-Presbyterian Medical Center
Study of tandem high dose chemotherapy and autologous blood stem cell transplantation for lymphoma

New York; Columbia-Presbyterian Medical Center
Phase III Randomized Trial of CHOP Chemotherapy with or without Rituximab (Chimeric Anti CD Antibody) for HIV Associated Non-Hodgkin's Lymphoma

New York; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Rexford; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Syracuse; SUNY Upstate Medical University
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Troy; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Ohio

Canton; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Columbus; Hematology & Oncology Associates
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Oklahoma

Lawton; Cleo Craig Memorial Cancer and Research Clinic
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Oregon

Oregon City; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Portland; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Tualatin; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Pennsylvania

Hershey; Milton S. Hershey Medical Center
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Philadelphia; Research Site
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R

South Carolina

Greenville; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Tennessee

Johnson City; McLeod Cancer and Blood Center
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Texas

Abilene; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Arlington; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Bedford; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Dallas; Baylor University Medical Center
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Dallas; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Ft. Worth; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Houston; UT, M.D. Anderson Cancer Center
A Phase 2 study comparing rituximab plus sargramostim to rituximab monotherapy for treatment of relapsed, follicular B-cell lymphoma.

Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Non-Hodgkin’s Lymphoma, Low Grade

Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Non-Hodgkin’s Lymphoma Intermediate Grade

Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Non-Hodgkin's Lymphoma, High Grade

Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Non-Hodgkin’s Lymphoma

New Braunfels; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Plano; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

San Antonio; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Tyler; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Virginia

Charlottesville; University of Virginia
Adults with Non-Hodgkins Lymphoma Sought for a Research Study.

Norfolk; Research Site
Study Comparing the Zevalin Regimen With No Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R

Washington

Bremerton; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Spokane; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Vancouver; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

West Virginia

Morgantown; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Wisconsin

Madison; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Marshfield; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Wausau; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

International

Tirana, Albania; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Bahia Blanca, Argentina; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Buenos Aires , Argentina; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Buenos Aires , Argentina; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Corrientes, Argentina; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

La Plata, Argentina; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

La Plata, Argentina; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Adelaide, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Ashford, SA, Australia; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Ballarat, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Brisbane, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Brisbane, Australia; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Canberra, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Darlinghurst, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Darlinghurst, NSW, Australia; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Elizabeth Vale, QLD, Australia; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Fitzroy, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Frankston, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Frankston, Melbourne, Australia; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Frankston, VIC, Australia; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Fremantle, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Geelong, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Gosford, Australia; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Gosford, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Greenslopes, Australia; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Heidelberg, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Herston, QLD, Australia; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Herston, QLD, Australia; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Hobart, Australia; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Hobart, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Liverpool, Australia; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Melbourne, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Melbourne, Australia; Research Site:
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)

Newcastle, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Parkville, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Perth, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Perth, Australia; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

South Brisbane, Australia; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

South Brisbane QLD, Australia; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

SouthPort, Goldcoast, Australia; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

St. Leonards, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Sydney, Australia; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Sydney, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Townsville, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Wodonga, Australia; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Wodonga, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Wollongong, Australia; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Wollongong, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Woodville South SA, Australia; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Woolloongabba, Australia; Research Site:
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)

Woolloongabba, Australia; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Bludesch, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Bregenz, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Dornbirn, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Fürstenfeld, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Graz, Austria; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Graz, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Graz, Austria; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Hall In Tirol, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Hohenems, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Innsbruck, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Innsbruck, Austria; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Klagenfurt, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Kufstein, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Leoben, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Linz, Austria; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Linz, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Oberpullendorf, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Oberwart, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Ried-Innkreis, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Salzburg, Austria; Research Site:
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.

Salzburg, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

St Pölten, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Steyr, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Villach, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Vöcklabruck, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Waidhofen A D Thaya, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Wels, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Wels, Austria; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Wien, Austria; Research Site:
A Study of MabThera (Rituximab) in Patients With HIV-Related Non-Hodgkin's Lymphoma

Wien, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Wien, Austria; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Wiener Neustadt, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Zams, Austria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Gomel, Belarus; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Minsk, Belarus; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Banja Luka, Bosnia and Herzegovina; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Banja Luka, Bosnia and Herzegovina; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Kasindo, Bosnia and Herzegovina; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Kasindo, Bosnia and Herzegovina; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Mostar, Bosnia and Herzegovina; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Sarajevo, Bosnia and Herzegovina; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Sarajevo, Bosnia and Herzegovina; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Belo Horizonte, Brazil; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Campinas, Brazil; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Campinas, Brazil; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Florianopolis, Brazil; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Goiania, Brazil; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Porto Alegre, Brazil; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Salvador, Brazil; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Sao Paulo, Brazil; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Sao Paulo, Brazil; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Sao Paulo, Brazil; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Pleven, Bulgaria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Plovdiv, Bulgaria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Sofia, Bulgaria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Sofia, Bulgaria; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Varna, Bulgaria; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Calgary, AB, Canada; Research Site:
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.

Calgary, AB, Canada; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Edmonton, AB, Canada; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Halifax, NS, Canada; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Hamilton, Canada; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Kingston, ON, Canada; Research Site:
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.

Kingston, ON, Canada; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

London, ON, Canada; Research Site:
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.

London, ON, Canada; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Montreal, QC, Canada; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Montreal, QC, Canada; Research Site:
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.

Ottawa, ON, Canada; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Quebec City, Canada; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Toronto, ON, Canada; Research Site:
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.

Toronto, ON, Canada; Research Site:
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)

Vancouver, BC, Canada; Research Site:
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.

Winnipeg, MN, Canada; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Hong Kong, China; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Bogota, Colombia; Research Site:
An Expanded Access Program of Neulastim (Pegfilgrastim)in Patients With Non-Hodgkin's Lymphoma

Bucaramanga, Colombia; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Rijeka, Croatia; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Split, Croatia; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Zagreb, Croatia; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Zagreb, Croatia; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Zagreb, Croatia; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Brno, Czech Republic; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Brno, Czech Republic; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Hradec Kralove, Czech Republic; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Ostrava, Czech Republic; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Praha, Czech Republic; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Praha, Czech Republic; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Praha 2, Czech Republic; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Hvidovre, Denmark; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Quito, Ecuador; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Cairo, Egypt; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Tallinn, Estonia; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Tartu, Estonia; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Espoo, Finland; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Haemeenlinna, Finland; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Kotka, Finland; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Kuopio, Finland; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Lahti, Finland; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Pori, Finland; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Angers, France; Research Site:
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

Besancon, France; Research Site:
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

Bordeaux, France; Research Site:
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

Clamart, France; Research Site:
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

Creteil, France; Research Site:
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)

Creteil, France; Research Site:
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

Dijon Cedex, France; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

La Roche Sur Yon, France; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Le Mans, France; Research Site:
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

Le Mans Cedex, France; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Lille, France; Research Site:
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)

Lille Cedex, France; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Lyon, France; Research Site:
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

Nantes, France; Research Site:
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

Nantes, France; Research Site:
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)

Neuilly-Sur-Seine, France; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Nice, France; Research Site:
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

Paris, France; Research Site:
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

Pierre Benite, France; Research Site:
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)

Pierre Benite, France; Research Site:
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

Pierre-Benite Cedex, France; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Poitiers, France; Research Site:
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

Rennes, France; Research Site:
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)

Rouen, France; Research Site:
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

Strasbourg, France; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Tours, France; Research Site:
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

Tours, France; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Tours Cedex, France; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Vandoeuvre-Les-Nancy, France; Research Site:
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

Augsburg, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Bad Soden, Germany; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Berlin, Germany; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Berlin, Germany; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Berlin, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Berlin, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Bochum, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Bonn, Germany; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Bonn, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Borna, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Braunschweig, Germany; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Chemnitz, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Cottbus, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Cottbus, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Dortmund, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Dresden, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Duisburg, Germany; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Dülmen, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Düsseldorf, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Erfurt, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Erfurt, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Erlangen, Germany; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Frankfurt, Germany; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Frankfurt Am Main, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Frankfurt An Der Oder, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Freiburg, Germany; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Freiburg, Germany; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Giessen, Germany; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Goettingen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Göttingen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Greifswald, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Greifswald, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Grenzach-Wyhlen, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma

Grenzach-Wyhlen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Güstrow, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Gütersloh, Germany; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Hagen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Halle, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Hamburg, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Hannover, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Heidelberg, Germany; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Heidelberg, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Homburg, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Jena, Germany; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Jena, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Jena, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Kiel, Germany; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Kiel, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Koeln, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Koln, Germany; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Landshut, Germany; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Leipzig, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Leipzig, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Lüdenscheid, Germany; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Ludwigshafen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Magdeburg, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Magdeburg, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Marburg, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Marburg, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Minden, Germany; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Minden, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Mönchengladbach, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Mülheim, Germany; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Munchen, Germany; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

München, Germany; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

München, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Münster, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Mutlangen, Germany; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Mutlangen, Germany; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Neubrandenburg, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Nordhausen, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Oldenburg, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Oldenburg, Germany; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Potsdam, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Recklinghausen, Germany; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Regensburg, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Riesa, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Rostock, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Schwäbisch-Hall, Germany; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Schwerin, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Stralsund, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Stuttgart, Germany; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Stuttgart, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Trier, Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Trier, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Ulm, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Villingen-Schwenningen, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Wiesbaden, Germany; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Würselen, Germany; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Zella-Mehlis , Germany; Research Site:
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Athens, Greece; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Ahmedabad, India; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Chisinau, India; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

New Delhi, India; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Panjagutta, India; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Parel, India; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Trivandrum, India; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Afula, Israel; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Beer Sheva, Israel; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Haifa, Israel; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Haifa, Israel; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Holon, Israel; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Jerusalem, Israel; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Jerusalem, Israel; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Jerusalem, Israel; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Kfar Saba, Israel; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Petah Tikva, Israel; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Petah Tikva, Israel; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Ramat Gan, Israel; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Ramat Gan, Israel; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Rehovot, Israel; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Tel Aviv, Israel; Research Site:
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma

Tel Aviv, Israel; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Tel Hashomer, Israel; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Bergamo, Italia; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Bologna, Italia; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Genova, Italia; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Milano, Italia; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Napoli, Italia; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Rome, Italia; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Rozzano, Italia; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Aviano, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Bari, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Bari, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Bergamo, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Biella, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Bologna, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Bologna, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Bolzano, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Brescia, Italy; Research Site:
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.

Brescia, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Brescia, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Brescia, Italy; Research Site:
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

Cagliari, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Cagliari, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Candiolo, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Candiolo, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Catania, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Catania, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Cremona, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Cuneo, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Ferrara, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Firenze, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Firenze, Italy; Research Site:
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

Firenze, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Genova, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Lecce, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Messina, Italy; Research Site:
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

Milano, Italy; Research Site:
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.

Milano, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Milano, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Milano, Italy; Research Site:
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

Modena, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Modena, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Monza, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Monza, Italy; Research Site:
A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Monza, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Napoli, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Napoli, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Novara, Italy; Research Site:
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.

Novara, Italy; Research Site
The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.

Novara, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Orbassano, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Padova, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Palermo, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Pavia, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Perugia, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Perugia, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Pesaro, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Pescara, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Pescara, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Pisa, Italy; Research Site:
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.

Pisa, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Pisa, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Reggio Calabria, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Reggio Calabria, Italy; Research Site:
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

Reggio Emilia, Italy; Research Site:
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

Reggio Emilia, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Rionero in Vulture, Italy; Research Site:
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

Roma, Italy; Research Site:
A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)

Roma, Italy; Research Site:
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

Roma, Italy; Research Site:
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Roma, Italy; Research Site:
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.<